Filtered By:
Condition: ALS

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 644 results found since Jan 2013.

Brain-Computer Interface after Nervous System Injury
This article presents a state-of-the-art review of BCI technology used after nervous system injuries, specifically: amyotrophic lateral sclerosis, Parkinson’s disease, spinal cord injury, stroke, and disorders of consciousness. Also presented is transcending, innovative research involving new treatment of neurological disorders.
Source: The Neuroscientist - November 11, 2014 Category: Neurology Authors: Burns, A., Adeli, H., Buford, J. A. Tags: Reviews Source Type: research

Nuedexta for the Treatment of Pseudobulbar Affect: Estimating the Financial Impact to the Scottish NHS
Pseudobulbar Affect (PBA) is a neurologic disorder of emotional expression, resulting in frequent and involuntary episodes of crying and/or laughing. Common neurological conditions associated with PBA include: Alzheimer’s disease, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, stroke and traumatic brain injury. Nuedexta® (Avanir Pharmaceuticals Inc. ) is the only EMA-approved PBA treatment. The financial impact of introducing Nuedexta to a national health care system, including Scotland, has never been formally estimated.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: C. Kiff, S. Mealing, M. Singh, S. Baculea, A. Badhan, C. Yonan Source Type: research

Dextromethorphan/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect
Abstract Fixed-dose dextromethorphan/quinidine capsules (Nuedexta®) utilize quinidine to inhibit the metabolism of dextromethorphan, enabling high plasma dextromethorphan concentrations to be reached without using a larger dose of the drug. The drug combination is the first treatment to be approved for pseudobulbar affect (PBA), a condition of contextually inappropriate/exaggerated emotional expression that often occurs in adults with neurological damage conditions, such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, traumatic brain injury, Alzheimer’s disease or Parkinson’s disease....
Source: Drugs - November 25, 2014 Category: Drugs & Pharmacology Source Type: research

Adipose Tissue Derived Stem Cells in Neural Regenerative Medicine.
In this study, several human clinical trials using ADSCs for neuronal disorders were investigated. It is suggested that ADSCs are one of the choices among various stem cells for translating into clinical application in the near future. PMID: 25647067 [PubMed - as supplied by publisher]
Source: Cell Transplantation - February 2, 2015 Category: Cytology Authors: Yeh DC, Chan TM, Harn HJ, Chiou TW, Chen HS, Lin ZS, Lin SZ Tags: Cell Transplant Source Type: research

Zinc: indications in brain disorders
This article is protected by copyright. All rights reserved.
Source: Fundamental and Clinical Pharmacology - February 1, 2015 Category: Drugs & Pharmacology Authors: Atish Prakash, Kanchan Bharti, Abu Bakar Abdul Majeed Tags: Review Article Source Type: research

UCLA researchers identify molecular ‘switch’ that causes Huntington’s disease–like symptoms in mice
This study makes clear that a major neuroprotective function of N17 is to prevent the mutant protein from entering the nucleus and eliciting more severe toxicities,” Yang said, adding that the result is consistent with findings from several studies of other, related disorders in which mutant proteins with expanded glutamine in the nucleus are key for jump-starting a disease. The researchers also found that the mice in the study experienced inflammation in the brain somewhat similar to that found in people with Huntington’s. “Neuroinflammation is emerging as a potentially shared mechanism in multiple neurodegenerative...
Source: UCLA Newsroom: Health Sciences - February 13, 2015 Category: Universities & Medical Training Source Type: news

From mice to mind: Strategies and progress in translating neuroregeneration.
Abstract Decisions about what experimental therapies are advanced to clinical trials are based almost exclusively on findings in preclinical animal studies. Over the past 30 years, animal models have forecast the success of hundreds of neuroprotective pharmacological therapies for stroke, Alzheimer׳s disease, spinal cord injury, traumatic brain injury and amyotrophic lateral sclerosis. Yet almost without exception, all have failed. Rapid advances in stem cell technologies have raised new hopes that these neurological diseases may one day be treatable. Still, how can neuroregenerative therapies be translated into ...
Source: European Journal of Pharmacology - March 23, 2015 Category: Drugs & Pharmacology Authors: Burns TC, Verfaillie CM Tags: Eur J Pharmacol Source Type: research

Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson's disease.
Abstract Sialorrhea or excessive drooling is a significant medical issue in Parkinson's disease (PD) and neurodegenerative disorders, although it is often underreported by patients. Sialorrhea affects a large proportion of PD patients, ranging up to 78% in advanced stages, with many PD patients considering drooling as their worst non-motor symptom. Sialorrhea affects up to a million patients with diverse neurological impairments, including cerebral palsy, amyotrophic lateral sclerosis (ALS), Huntington's, survivors of stroke and severe traumatic brain injury. Numerous approaches have been attempted to treat sialor...
Source: Current Topics in Medicinal Chemistry - April 4, 2015 Category: Chemistry Authors: Farber NM, Perez-Lloret S, Gamzu ER Tags: Curr Top Med Chem Source Type: research

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (I8-1B)
CONCLUSIONS: Interim evaluation of the primary objective-safety/tolerability and secondary objective-clinical endpoint responsiveness of MN-166 60 mg/day versus placebo administered for six months with riluzole in subjects with ALS will be presented for the first 30 patients. Study Supported by: Medicinova and Carolinas ALS Research FundDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Bravver has nothing to disclose. Dr. Sanjak has nothing to disc...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Sanjak, M., Langford, V., Lary, C., Alwan, M., Nemeth, J., Russo, P., Smith, N., Lucas, N., Nichols, M., Belcher, S., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Matsuda, Tags: Advances in ALS and Other Motor Neuron Diseases Data Blitz Presentations Source Type: research

Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study (P3.155)
Conclusions: This long-term prospective observational study of a wide cohort of patients confirms that ultrasonographically guided BoNT-A injections represents an effective and safe treatment for sialorrhea in different neurologic disorders.Disclosure: Dr. Barbero has nothing to disclose. Dr. Artusi has nothing to disclose. Dr. De Mercanti has nothing to disclose. Dr. Tinivella has nothing to disclose. Dr. Busso has nothing to disclose. Dr. Clerico has nothing to disclose. Dr. Durelli has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Barbero, P., Artusi, C. A., De Mercanti, S., Tinivella, M., Busso, M., Clerico, M., Durelli, L. Tags: Neuromuscular Disease: Therapeutics Source Type: research

Amyotrophic Lateral Sclerosis (ALS) with Laboratory Abnormalities of Unknown Significance (LAUS) --Where Does It Begin and Where Does It End? (P4.144)
CONCLUSIONS: Further detailed analysis of progression rate by site of onset, sex, age, treatment will require assimilation of clinic-based datasets of properly analyzed ALS-LAUS patients from multiple clinic sites. The appropriate role of IVIg in ALS-LAUS patients requires further study following explication of the natural history of these patients compared with non-ALS-LAUS patients. The determination as to whether auto-antibodies to additional antigens may play a role in the progression rate of ALS-LAUS compared with sporadic ALS needs to be systematically studied. Study Supported by: Carolinas ALS Research FundDisclosur...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Langford, V., Alwan, M., Smith, N., Lucas, N., Nichols, M., Belcher, S., Lary, C., Nemeth, J., Russo, P., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Sanjak, M. Tags: Neuroepidemiology: ALS Source Type: research

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (S50.005)
CONCLUSIONS: Interim evaluation of the primary objective-safety/tolerability and secondary objective-clinical endpoint responsiveness of MN-166 60 mg/day versus placebo administered for six months with riluzole in subjects with ALS will be presented for the first 30 patients. Study Supported by: Medicinova and Carolinas ALS Research FundDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Bravver has nothing to disclose. Dr. Sanjak has nothing to disc...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Sanjak, M., Langford, V., Lary, C., Alwan, M., Nemeth, J., Russo, P., Smith, N., Lucas, N., Nichols, M., Belcher, S., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Matsuda, Tags: Treatment Trials in Neuromuscular Diseases Source Type: research

Interplay Between Exosomes, microRNAs and Toll-Like Receptors in Brain Disorders
Abstract Extracellular vesicles (EVs), including exosomes, microvesicles and apoptotic bodies, participate in intercellular communication, and particularly, in paracrine and endocrine signalling. The EVs and their specific contents have been considered hallmarks of different diseases. It has been recently discovered that EVs can co-transport nucleic acids such as DNAs, ribosomal RNAs, circular RNAs (circRNAs), long noncoding RNAs (lnRNAs) and microRNAs (miRNAs). miRNAs are important regulators of gene expression at the post-transcriptional level, although they may also play other roles. Recent evidence supports th...
Source: Molecular Neurobiology - April 11, 2015 Category: Neurology Source Type: research

Female gender doubles executive dysfunction risk in ALS: a case-control study in 165 patients
Conclusions Results highlight a significant vulnerability of ALS female patients to develop cognitive dysfunctions peculiar to the disease, independently of bulbar onset. The explicative hypotheses of the data are focused on two interpretative lines not mutually exclusive: the role of gonadal hormones and gender-related brain asymmetry pre-existing to the disease. These findings, never reported before in the literature, can have important implications for models of ALS pathogenesis and for future clinical trial designs.
Source: Journal of Neurology, Neurosurgery and Psychiatry - April 13, 2015 Category: Neurosurgery Authors: Palmieri, A., Mento, G., Calvo, V., Querin, G., D'Ascenzo, C., Volpato, C., Kleinbub, J. R., Bisiacchi, P. S., Soraru, G. Tags: Motor neurone disease, Neuromuscular disease, Spinal cord, Stroke, Memory disorders (psychiatry) Cognitive neurology Source Type: research

Tracking Healthcare Utilization (Cost) In Pseudobulbar affect Patients treated with Nuedexta
Pseudobulbar affect (PBA) is an underdiagnosed condition characterized by sudden, involuntary episodes of crying and/or laughing in patients with traumatic brain injury or certain neurologic diseases, including multiple sclerosis, amyotrophic lateral sclerosis, stroke, Alzheimer’s disease, and others. Studies suggest that PBA symptoms are associated with added healthcare utilization and costs. NUEDEXTA (dextromethorphan/quinidine) is the only FDA and EMA approved PBA treatment. The primary objective of this analysis is to evaluate healthcare utilization and costs in PBA patients before and after dextromethorphan/quinidine treatment.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: M Palmgren, A Cyhaniuk, C Yonan, E Potente Source Type: research